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was carried out by multiple-reaction-monitoring (MRM) mode
of positive tandem mass spectrometry with mass transitions of
m/z 207>178 for the derivatized MX and m/z 210>181 for the
derivatizedMX-d3, respectively. The LC–MS/MSmethoddeveloped
permitted batch sample preparation and baseline resolution for the
analytes from the derivatizing agent and other endogenous com-
pounds in plasma, which has been fully validated and successfully
applied to the first-in-human PK study of MX.
Experimental
Chemicals and solutions
LC/MS-grade acetonitrile, HPLC-grade water, and HPLC-grade
methyl tert-butyl ether were purchased from Fisher Scientific
(Pittsburgh, PA, USA). Methoxyamine hydrochloride, formic acid,
acetic acid, phosphoric acid, hydrochloric acid, and 4-(N,N-
diethylamino)benzaldehyde were from Sigma–Aldrich (St. Louis,
MO, USA). Methoxyl-d3-amine hydrochloride was from C/D/N Iso-
topes Inc. (Pointe-Claire, Quebec, Canada). Temozolomide (CAS
registry # 85622-93-1) was obtained from the Developmental
Therapeutics Program at the National Cancer Institute (Rockville,
MD, USA). Pooled human plasma containing no detectable MXwas
obtained from Fisher Scientific (Pittsburgh, PA, USA) and used as
blank plasma. Six randomly selected pre-dosed patients’ plasma
samples were used as six sources of human plasma matrices for
the studies of the selectivity and the lower limit of quantitation
(LLOQ) of the method. Six individual human plasmas contain-
ing no detectable MX (i.e., 1M2070-01, 1M2070-02, 1M2070-03,
1M2070-04, 1M2070-05, and1M2070-06)were also obtained from
Innovative Research (Novi, MI, USA) for the study of matrix effect.
The stock solution of MX (2.00mg/ml) was prepared by
dissolving appropriate amount of methoxyamine hydrochloride
(CH3ONH2·HCl) with a mass correction factor of 0.563 in a known
volume of 0.100N hydrochloric acid. The stock solution of MX-
d3 (2.00mg/ml) was prepared by dissolving appropriate amount
of methoxyl-d3-amine hydrochloride (CD3ONH2·HCl) with a mass
correction factor of 0.579 in a known volume of 0.100N hydrochlo-
ric acid. The stock solution of 4-(N,N-diethylamino)benzaldehyde
(200mg/ml)was prepared by dissolving appropriate amount of the
compound in a known volume of 66.7% acetic acid. The stock solu-
tion of TMZ (5.00mg/ml) was prepared by dissolving appropriate
amount of TMZ in 0.100N hydrochloric acid. Theworking standard
solutions of MX (5.00g/ml, 500ng/ml, and 50.0ng/ml) were pre-
pared by a serial dilution of the stock solution of MX (2.00mg/ml)
with0.100Nhydrochloric acid. Theworking internal standard solu-
tion of MX-d3 (100ng/ml) was prepared from the serial dilution of
the stock solutionofMX-d3 (2.00mg/ml)with0.100Nhydrochloric
acid. The working solution of 4-(N,N-diethylamino)benzaldehyde
(500g/ml) was prepared from the serial dilution of stock solu-
tion of 4-(N,N-diethylamino)benzaldehyde (200mg/ml)with 33.3%
formic acid. Theworking solutionof TMZ (500g/ml)wasprepared
by diluting the stock solution of TMZ (5.00mg/ml) with 0.100N
hydrochloride acid. The mobile phase was prepared by mixing
450ml of LC/MS-grade acetonitrile, 550ml of HPLC-grade water,
and 4ml of formic acid.
Preparation of plasma calibrators and quality controls
Plasma MX calibrators (1.25, 2.50, 5.00, 12.5, 25.0, 50.0, 125,
250 and 500ng/ml) were prepared by dilution of the working
standard solutions of MX (50.0, 500 and 5.00×103 ng/ml) with
blank plasma and 0.100N hydrochloric acid to ensure each cali-
brator containing exactly 90% (in volume) of plasma and 10% of
0.100Nhydrochloric acid. PlasmamatrixblankandplasmaMXzero
calibrator samples were prepared to contain 90% (in volume)
of plasma and 10% of 0.100N hydrochloric acid. The plasma
MX QCs (3.50, 45.0 and 450ng/ml) and plasma MX dilution QC
(1.50×103 ng/ml) were prepared in the same manner as that
of the plasma calibrators. Plasma MX calibrators (150l), QCs
(150l) and dilution QCs (30l) were stored in small aliquotswith
cappedborosilicate glass tubes (13mm×100mm,Fisher Scientific)
at−70 ◦Cbeforeuse. TheMXdilutionQCsamples (1.50×103 ng/ml,
30l)weredilutedbya factor of 5with120-l pooledhumanblank
plasma prior to sample preparation.
Plasma TMZ control (20.0g/ml) was prepared by diluting the
working solution of TMZ (500g/ml) with pooled human blank
plasma. PlasmaMX QCs (3.50, 45.0 and 450ng/ml) containing TMZ
(20.0g/ml) were prepared in the same manner as that of the
plasma MX QCs except using plasma TMZ control instead of blank
plasma as a diluent.
Sample preparation
Each aliquot of 150l plasma sample (i.e., plasma calibrators,
plasma QCs, or patient plasma samples) was mixed with 75l of
working internal standard solution of MX-d3 (100ng/ml), 50l of
4-(N,N-diethylamino)benzaldehydeworking solution (500g/ml),
and 150l of 4% phosphoric acid (v/v) in a borosilicate glass tube
with cap. The mixture was heated at 70 ◦C for 1h in a dry-bath
incubator (Denville Scientific, Roebling,NJ, USA) and thenextracted
with 2ml of methyl tert-butyl ether. The organic phase was trans-
ferred into a fresh borosilicate glass tube (12mm×75mm, Fisher
Scientific) which was then dried in a TurboVap® LV evaporator
(Caliper Life Sciences, Hopkinton, MA, USA) at 30 ◦C under nitrogen
gas pressure of 15psi for ca. 15min. The residue was then recon-
stituted in 150l of aqueous solution containing 10% acetonitrile
and 1% formic acid for LC–MS/MS analysis.
Instrumentation
The instrumentation system used consisted of a Shimadzu SIL-
20AC autosampler (Shimadzu, Columbia, MD, USA), a Shimadzu
LC-20AD HPLC unit with Waters XTerra® MS C18 precolumn
(2.1mm×10mm, 3.5m) and Waters XTerra® MS C18 column
(2.1mm×100mm, 3.5m) (Waters, Milford, MA, USA), and an AB
Sciex API 3200 turbo-ion-spray® triple quadrupole tandem mass
spectrometer (AB Sciex, Foster City, CA, USA). The systemwas con-
trolled by AB Sciex Analyst® (version 1.5.1) software.
The API 3200 tandem mass spectrometer was operated under
the positive turbo-ion-spray ionization mode. It was tuned by
a reaction mixture of 500ng/ml MX, 500ng/ml MX-d3, and
500g/ml 4-(N,N-diethylamino)benzaldehyde in 45% acetonitrile
and 1% formic acid aqueous solution for both the compound-
dependent and the source-dependent parameters. MRM data were
acquiredwith the followingmass transitions and optimized instru-
ment settings: m/z 207>178 for the derivatized MX, m/z 210>181
for the derivatized MX-d3, and m/z 178>134 for the derivatizing
agent; curtain gas (CUR) at 25, collision assisted dissociation gas
(CAD) at 5; ionization voltage (IS) at 5500V; source temperature
(TEM) at 550; sheath gas (GS1) at 40; desolvation gas (GS2) at 45;
desolvation potential (DP) at 36; entrance potential (EP) at 3.5; col-
lision energy (CE) at 21; collision cell exit potential (CXP) at 4; and
resolution at unit.
Analytical separation of the derivatized analytes was accom-
plished on a XTerra® MS C18 column by isocratic elution with the
mobile phase at a flow rate of 0.200ml/min. During each run, 5l of
reconstituted samplewas injected into the systemby the autosam-
pler set at 15 ◦C. The two-position switch valve on the API 3200
tandemmass spectrometer was programmed to direct the column
eluate to the mass spectrometer for the first 4min, then switch to
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the waste for the next 3 min, and return to the mass spectrometer
for the last 2 min  during each run. Quantitation of the derivatized
analytes was carried out with MRM  mode of the tandem mass spec-
trometer. The total instrument run time for each sample analysis
was 9 min. Prior to initial sample analysis, the column was equi-
librated with the mobile phase at the above flow rate for at least
30 min.
Data  analysis
Data  acquisition and peak integration were done using the
Analyst® software with IntelliQuan-MQII algorithm. The peak area
ratios of the derivatized MX to the derivatized MX-d3 (IS) were
plotted against the MX  concentrations in plasma calibrators for a
linear regression calibration equation using a weighting factor of
1/x2. The MX  concentration in a patient’s sample was calculated by
the Analyst® software using the peak area ratio of the derivatized
MX to that of the derivatized IS and the calibration equation.
Stability studies
The  stability of MX stock solution (2.00 mg/ml) in refrigerator
(4 ◦C) and at benchtop (23 ◦C), and the stability of plasma QCs (3.50,
45.0 and 450 ng/ml) at benchtop (23 ◦C), in autosampler (15 ◦C), by
freeze-and-thaw cycles (−70–23 ◦C), and in deep freezer (−70 ◦C)
were investigated over various time periods.
Pharmacokinetic study
In  the phase I clinical trial of MX  and TMZ  in patients with
advanced solid tumors, all patients enrolled have been histologi-
cally confirmed solid tumors that were considered incurable and
were not amenable to conventional surgical, radiation therapy or
chemotherapy treatment programs.
Two dosing regimens of MX  have been examined in the phase
I clinical trial. Initially, patients were given MX  as an iv contin-
uous infusion (15 mg/m2/day) for 5 days in combination with an
oral dose of TMZ  (100 mg/m2/day) for 5 days on a 28-day cycle.
The dosing regimen of MX  was amended from a 5-day iv contin-
uous infusion to a single 1-h iv infusion (15 mg/m2) after first six
patients. Dose-escalation of both MX  and TMZ  followed the sched-
ule specified in the CASE 1Y05 protocol [6].
In the clinical trial, patients were given MX within 5 min  of tak-
ing an oral dose of TMZ. Blood samples were drawn before and after
MX administration according to the schedules specified in the CASE
1Y05 protocol. Plasma samples were collected for MX  analysis by
the procedure as follows: drew 3 ml  of blood into a labeled lithium
heparinized tube (green top) at each sampling time point, and kept
all sample tubes in an ice bath before centrifugation; centrifuged
the blood samples at 1500 × g at 4 ◦C for 5 min; transferred the
plasma into a labeled Nunc® CryoTube® vial; capped and mixed the
sample tubes; and stored the sample tubes immediately at −70 ◦C
until LC–MS/MS analysis.
Pharmacokinetic modeling was done by Phoenix WinNon-
Lin (Version 6.2) software from Pharsight Corporation (St. Louis,
MO, USA). The 120-h iv infusion data fitted well with the PK
model 2 (one-compartment iv-infusion, no lag time, first-order
elimination), and the 1-h iv infusion data were modeled by non-
compartmental analysis (NCA).
Results and discussion
LC–MS/MS  method development
Although  the measurement of MX  in plasma samples had been
reported by the FIA-MS/MS method [10]; however, there were
several  shortcomings of this method when applied to large-batch
clinical samples, including: (a) frequent clogging of the in-line fil-
ter by plasma proteins, which required replacement of the filter
to avoid pressure fluctuation of the system; (b) a large amount of
unreacted derivatizing agent 4-(N,N-diethylamino)benzaldehyde
presented in the plasma samples (ca. 16.7 g of the derivatizing
agent in each 10 l sample injection), which could be co-extracted
and co-eluted on/from the on-line SPE cartridge with the deriva-
tized MX  and IS, and harmful to a mass spectrometer if it entered
on a routine basis; and (c) the matrix effect of the co-eluted of
derivatizing agent and other endogenous compounds, which could
suppress ionization of the derivatized MX  and IS in mass spec-
trometer; and (d) the on-line SPE of the FIA-MS/MS method [10],
which made sample re-run impossible in case of instrument fail-
ures. Therefore, an LC–MS/MS method has been developed, which
uses methyl tert-butyl ether as organic solvent for the extrac-
tion of the derivatized MX  and IS, and a Waters XTerra® MS
C18 column (2.1 mm ×100 mm,  3.5 m) for analytical separation
of the derivatized analytes from the derivatizing agent 4-(N,N-
diethylamino)benzaldehyde and other endogenous compounds.
Derivatizing agent 4-(N,N-diethylamino)benzaldehyde
The derivatization reaction between MX  and 4-(N,N-
diethylamino)benzaldehyde is a Schiff reaction [9]. In order
to consume all Schiff reagent (MX), excess amount of 4-(N,N-
diethylamino)benzaldehyde had been used [10]. As discussed
in Section 3.1, the unreacted derivatizing agent in plasma
samples could have an adverse effect on mass spectrometric
detection. Therefore, the reaction between MX and 4-(N,N-
diethylamino)benzaldehyde has been further optimized. In this
work, the amount of the derivatizing agent was lowered by
20 times from a 1000-fold excess in the FIA-MS/MS method
[10] to a 50-fold excess in the current method. The lower
amount of the derivatizing agent was proven by the method
validation data (see later sections) to be sufficient to drive
the derivatization reaction to completion in plasma matrix
under 70 ◦C for 1-h duration. Thus, 50 l of 500 g/ml 4-(N,N-
diethylamino)benzaldehyde solution has been adopted for
plasma MX derivatization in the LC–MS/MS method (see Section
2.3).
It was  also found that the addition of 4% phosphoric acid to a
plasma sample stabilized acidic medium required for the derivati-
zation reaction, and helped to increase the clarity of the solution in
the later LLE.
Liquid–liquid extraction and reconstitution of sample
extract
The  derivatized MX and IS were extracted from plasma by an LLE
procedure. To find a better organic solvent, both ethyl acetate and
methyl tert-butyl ether were tested. Methyl tert-butyl ether was
found to be the one because it gave not only a higher extraction
recovery for the derivatized MX  and IS, but also a clearer solution
of the reconstituted extract prepared in the later step in comparison
to ethyl acetate. Therefore, methyl tert-butyl ether was  chosen as
the organic solvent for the LLE.
To reconstitute the dry extract after solvent evaporation, an
aqueous solution of 10% acetonitrile and 1% formic acid was  used.
This solution had a lower organic content than that of the mobile
phase. Therefore, it did not contribute to chromatographic peak
broadening.
Mass spectrometric detection
In this work, the derivatized MX,  the derivatized IS, and
the derivatizating agent 4-(N,N-diethylamino)benzaldehyde were
readily protonated in the acidic conditions. Therefore, the positive
turbo-ion-spray ionization mode was used for identification and
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Fig. 1. MX derivatization reaction, and mass spectra (product ions) of the derivatized MX (A), the derivatized MX-d3 (B), and the derivatizing agent 4-(N,N-
diethylamino)benzaldehyde (C). The experimental conditions were the same as those described in Section 2.4.
quantitation of the analytes. As shown in the mass scans of the
product ions (Fig. 1), the major fragments were m/z 178 for the
derivatized MX (Fig. 1A), m/z 181 for the derivatized IS (Fig. 1B),
and m/z 134 for the derivatizing agent (Fig. 1C) by selecting pre-
cursor ions at m/z 207 for the derivatized MX, m/z 210 for the
derivatized IS, and m/z 178 for the derivatizing agent, respectively.
Hence,mass transitionsofm/z207>178 for thederivatizedMX, and
m/z 210>181 for the derivatized IS were chosen for the determi-
nation of MX by MRM mode; and mass transition of m/z 178>134
for the derivatizing agent was chosen for the interference study.
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Fig. 2. The effect of formic acid in the mobile phase on the chromatographic separation of the derivatized MX and the derivatizing agent 4-(N,N-diethylamino)benzaldehyde:
(A)  mass chromatogram of MX,  no formic acid added; (B) mass chromatogram of the derivatizing agent, no formic acid added; (C) mass chromatogram of MX,  0.4% formic
acid  added; and (D) mass chromatogram of the derivatizing agent, 0.4% formic acid added. Mass transitions: m/z  207 > 178 for the derivatized MX,  and m/z  178 > 134 for the
derivatizing agent.
Chromatographic separation
Separation of the derivatized MX  and 4-(N,N-
diethylamino)benzaldehyde was done on a Waters Xterra C18
column (2.1 mm × 100 mm,  3.5 m)  using a mobile phase con-
taining 45% acetonitrile at a flow rate of 0.2 ml/min. The addition
of formic acid in the mobile phase could affect the elution order
of the derivatized MX  and 4-(N,N-diethylamino)benzaldehyde
(Fig. 2). When no formic acid was added to the mobile phase,
the peak of the derivatized MX (Fig. 2A) overlapped with that of
4-(N,N-diethylamino)benzaldehyde (Fig. 2B). Moreover, the peak
of the derivatized MX was severely suppressed and broadened
(Fig. 2A) due to the presence of a large amount of 4-(N,N-
diethylamino)benzaldehyde in the sample. When formic acid
was added in the mobile phase, the peak of the derivatized
MX (Fig. 2C) not only eluted out of the column earlier than
that of 4-(N,N-diethylamino)benzaldehyde (Fig. 2D), but also
the peak of the derivatized MX was sharpened (Fig. 2C). In this
method, the formic acid concentration was optimized to be
0.4% in the mobile phase of 45% acetonitrile. This mobile phase
gave retention times of 2.6 and 5.6 min  on the Waters Xterra
C18 column for the derivatized MX and the derivatizing agent
4-(N,N-diethylamino)benzaldehyde, respectively. Therefore, the
matrix effect from 4-(N,N-diethylamino)benzaldehyde on the mass
spectrometric detection of the derivatized MX could be avoided.
Furthermore, to prevent contamination to the mass spectrom-
eter, the eluate containing 4-(N,N-diethylamino)benzaldehyde
was diverted to waste from the run times of 4.0 to 7.0 min
by programming the two-position switch valve on the mass
spectrometer.
Method validation
The  LC–MS/MS method was validated according to the guide-
lines for bioanalytical method validation set forth by the FDA and
the industry [11–13].
Specificity and LLOQ
The  specificity of the method was evaluated by the pre-dosed
plasma samples from patient donors. In the CASE 1Y50, more than
50 patient pre-dosed plasma samples were collected and analyzed,
there were no detectable interferences observed at the mass tran-
sitions and the retention times of the derivatized MX  and IS. Fig. 3
shows the representative mass chromatograms of human plasma
matrix blank (Fig. 3A and B), zero plasma MX  calibrator with the IS
(Fig. 3C and D), and two  non-zero plasma MX  calibrators with the
IS (Fig. 3E–H).
In  this work, the LLOQ of the method was defined by the low-
est concentration of plasma MX calibrator (1.25 ng/ml). Table 1
shows the accuracy and precision of the method at LLOQ, which
were defined as percent relative error (%RE) and correlation coef-
ficient (%CV). By five replicate measurements of each individual
plasma matrix, the mean accuracy and precision from six individual
pre-dosed patient plasma matrices were ≤−0.8% and ≤0.8%, respec-
tively. These values were much lower than those of the industry
limits (±20% and 20%), and implied that the actual LLOQ of the
method could be lower than 1.25 ng/ml.
Matrix factor and recovery
Matrix factor is a measure of matrix effect in a sample. Absolute
matrix factor (MF) was determined by the mean-peak area of the
derivatized MX  in extracted plasma matrix over the mean-peak
area of the derivatized MX  in mobile phase; and IS normalized MF
was determined by the MF  of the derivatized MX over the MF  of the
derivatized IS. Whereas, absolute recovery was  determined by the
mean-peak area of the derivatized MX in plasma sample over the
mean-peak area of the derivatized MX  in extracted plasma matrix,
and IS normalized recovery was  determined by the recovery of the
derivatized MX over the recovery of the derivatized IS.
Because  MX-d3, a stable isotope of MX,  was  the IS in this work,
the pooled human plasma instead of 6 individual sources was ini-
tially used as sample matrix for the studies of matrix effect and
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Fig. 3. The representative mass chromatograms of the derivatized MX and IS in human plasma samples: (A, B) plasma matrix blank (with neither MX nor IS); (C, D) plasma
zero calibrator with IS (50.0 ng/ml); (E, F) plasma MX at LLOQ (1.25 ng/ml) with IS; and (G, H) patient sample with IS at 70-min sampling point by the dosing regimen of MX
(single 1-h iv infusion), 15 mg/m2/day; and TMZ  (oral once daily), 100 mg/m2/day for 5 days.
recovery. In these studies, MX  samples at three concentrations
(3.50, 45.0 and 450 ng/ml) were prepared in the pooled human
plasma, the extracted pooled human plasma, and the mobile phase;
then, subjected to the procedure described in Section 2.3 before
the LC–MS/MS analyses. As seen in Table 2, the absolute MFs  were
0.42–0.54 for the derivatized MX and 0.42–0.56 for the deriva-
tized IS; and the IS normalized MFs  was 0.96–1.02. These data
indicated  that signal suppression did occur in plasma matrix by
nearly 50%; however, the use of internal standard could correct
the signal suppression by nearly 100%. In terms of recoveries
(Table 3), high and consistent absolute recoveries (84–100% for
the derivatized MX and 84–98% for the derivatized IS), and near
100% IS normalized recoveries (100–102%) were achievable by the
method.
Table 1
Accuracy and precision of MX at LLOQ in six patients’ pre-dosed plasmas (n = 5).
Pre-dosed patient plasma Nominal [MX] (ng/ml) Measured [MX] (ng/ml) SD (ng/ml) %CV %RE
#1 1.25 1.26 0.04 3 0.8
#2  1.25 1.23 0.03 2 −2
#3  1.25 1.24 0.02 2 −0.8
#4 1.25  1.29 0.03 2 3
#5  1.25 1.21 0.03 2 −3
#6  1.25 1.23 0.04 3 −2
Meana 1.25 1.24 0.01 0.8 −0.8
a X = (x1 + x2 + . . .x6)/6; SD =
(√
(sd21 + sd22 + sd23 + sd24 + sd25 + sd26
)
/6; %CV = SD/X; %RE = [(measured value − nominal value)/(nominal value)] × 100%.
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Table  2
Matrix effect on MX  QC samples in the pooled blank human plasma (n = 5).
MX QC
(ng/ml)
PAMX in extracted
plasma ± SD (×105)a
PAMX in mobile
phase ± SD (×105)
MFMX ± SDb PAIS in extracted
plasma ± SD (×105)
PAIS in mobile
phase ± SD (×105)
MFIS ± SDb IS normalized
MF ± SDb
3.50 0.40 ± 0.02 0.960 ± 0.005 0.42 ± 0.02 5.7 ± 0.2 13.4 ± 0.1 0.42 ± 0.02 1.00 ± 0.07
45.0 6.8  ± 0.3 12.5 ± 0.3 0.54 ± 0.03 7.5 ± 0.4 13.4 ± 0.2 0.56 ± 0.03 0.96 ± 0.07
450  52.0 ± 0.5 101 ± 2 0.51 ± 0.01 6.00 ± 0.09 11.9 ± 0.3 0.50 ± 0.01 1.02 ± 0.03
a PA, mean peak area.
b Priya y (±sy) = [a(±sa)/b(±sb)], sy = y ·
√
(sa/a)
2 + (sb/b)2.
Table 3
Recovery of MX from QC samples in the pooled blank human plasma (n = 5).
MX QC
(ng/ml)
PAMX in plasma ± SD
(×105)
PAMX in extracted
plasma ± SD (×105)
RecoveryMX ± SD
(%)a
PAIS in plasma ± SD
(×105)
PAIS in extracted
plasma ± SD (×105)
RecoveryIS ± SD
(%)b
IS normalized
recovery ± SD (%)c
3.50 0.40 ± 0.03 0.40 ± 0.02 100 ± 9 5.6 ± 0.4 5.7 ± 0.2 98 ± 8 102 ± 12
45.0  5.7 ± 0.3 6.8 ± 0.3 84 ± 6 6.3 ± 0.3 7.5 ± 0.4 84 ± 6 100 ± 10
450 49.8 ±  0.6 52.0 ±  0.5 96 ±  1 5.7 ±  0.1 6.00 ± 0.09 95 ± 2 101 ± 2
a Recovery of MX  = [(PA of MX  in plasma matrix)/(PA of MX in extracted plasma matrix)] ×100%.
b Recovery of IS = [(PA of IS in plasma matrix)/(PA of IS in extracted plasma matrix)] × 100%.
c IS normalized recovery = [(recovery of MX)/(recovery of IS)] × 100%.
Table 4
Matrix effect on MX  QCs in six individual lots of blank human plasma matrices (n = 5).
Plasma matrix MX QC (ng/ml) MFMX ± SDa MFIS ± SDb IS normalized MF  ± SDc
Lot 1 3.50 1.7 ± 0.1 1.7 ± 0.1 1.0 ± 0.1
45.0  1.5 ± 0.1 1.44 ± 0.09 1.0 ± 0.1
450  1.4 ± 0.1 1.4 ± 0.1 1.0 ± 0.1
Lot  2 3.50 1.27 ± 0.09 1.25 ± 0.08 1.0 ± 0.1
45.0  1.24 ± 0.09 1.23 ± 0.08 1.0 ± 0.1
450 1.3 ±  0.1 1.3 ±  0.1 1.0 ±  0.1
Lot  3 3.50 0.82 ± 0.09 0.80 ± 0.08 1.0 ± 0.1
45.0 0.71  ± 0.05 0.71 ± 0.05 1.0 ± 0.1
450  0.74 ± 0.08 0.75 ± 0.08 1.0 ± 0.2
Lot  4 3.50 0.9 ± 0.1 0.9 ± 0.1 1.0 ± 0.2
45.0  0.77 ± 0.09 0.77 ± 0.09 1.0 ± 0.2
450  0.82 ± 0.07 0.82 ± 0.07 1.0 ± 0.1
Lot  5 3.50 0.67 ± 0.08 0.66 ± 0.08 1.0 ± 0.2
45.0  0.71 ± 0.08 0.71 ± 0.07 1.0 ± 0.2
450 0.8  ± 0.1 0.8 ± 0.1 1.0 ± 0.2
Lot  6 3.50 0.84 ± 0.09 0.82 ± 0.08 1.0 ± 0.1
45.0  0.70 ± 0.09 0.70 ± 0.08 1.0 ± 0.2
450  0.75 ± 0.08 0.75 ± 0.08 1.0 ± 0.2
a MFMX = (mean peak area of MX in the extracted plasma matrix)/(mean peak area of MX in the mobile phase).
b MFIS = (mean peak area of IS in the extracted plasma matrix)/(mean peak area of IS in the mobile phase).
c IS normalized MF = MFMX/MFIS.
Matrix effects in six individual lots of human blank plasma
were also determined per reviewer’s request. As shown in Table 4,
even though the absolute MFs  of the derivatized MX  and IS
ranged from 0.66 to 1.7, the IS normalized MFs  were 1.0. These
results revealed that either signal suppression or enhancement
could occur in each individual human plasma samples. The use
of MX-d3 as the IS could normalize MFs  in the samples to
unity.
Calibration curve
MX  calibration curve in human plasma was  constructed using
a plasma matrix blank (with neither MX nor IS), a zero plasma
calibrator (with only IS), and 9 non-zero plasma calibrators (with
MX and IS). The IS concentration was 50.0 ng/ml, and the MX
concentrations of the non-zero calibrators were 1.25, 2.50, 5.00,
12.5, 25.0, 50.0, 125, 250 and 500 ng/ml. The linear calibration
range of 1.25–500 ml  was established in human plasma by plot-
ting the peak-area ratios of the derivatized MX to the derivatized IS
versus the concentrations of MX.  The calibration equation derived
from five individual calibration curves from five validation batches
with 1/x2 weighting was Y = 0.0174(±0.0002)X + 0.0006(±0.0001)
with a correlation coefficient ≥ 0.993. The accuracy and precision of
individual calibrators in human plasma as summarized in Table 5
were ≤±3% and ≤3%, respectively.
Accuracy  and precision
The intra-run accuracy and precision were determined by 6
replicate measurements of a QC sample at each QC concentration
(3.50, 45.0, 450, and 1.50 × 103 ng/ml) within a validation batch.
The inter-run accuracy and precision were determined by 5 paral-
lel measurements of 5 identical QC samples at each concentration
Table 5
Accuracy and precision of MX plasma calibrators over five validation batches.
MX  calibrator (ng/ml) Measured [MX] (ng/ml) SD (ng/ml) %CV %RE
1.25 1.27 0.02 3 2
2.50 2.44 0.06 2 −2
5.00 4.95 0.1 2 −1
12.5 12.2 0.2 2 −2
25.0 24.3 0.5 2 −3
50.0 51.2 0.4 0.8 2
125 125 1 0.8 0
250 253 1 0.4 1
500 513 7 1 3
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Table 6
Intra- and inter-run accuracy and precision of plasma MX QC samples.
MX QC (ng/ml) Measured [MX] (ng/ml) SD (ng/ml) %CV %RE
Intra-day (n=6)
3.50 3.50 0.04 1 0
45.0 46.4 0.4 0.9 3
450 458 5 1 2
1.50×103 1.50×103 2×101 1 0
Inter-day (n=5)
3.50 3.55 0.03 0.8 1
45.0 46.0 1 3 2
450 466 4 0.9 4
1.50×103 1.54×103 2×101 1 3
Table 7
The interference study of TMZ on the measurement of MX in human plasma (n=5).
MX QC (ng/ml) 3.50 45.0 450
TMZ (20.0g/ml) Yes No Yes No Yes No
Measured [MX] (ng/ml) 3.58 3.65 46.8 47.5 477 475
SD (ng/ml) 0.05 0.03 0.9 0.7 6 6
%CV 1 1 2 1 1 1
%RE 2 4 4 6 6 6
(3.50, 45.0, 450, and 1.50×103 ng/ml) over five validation batches.
As shown in Table 6, the intra-run accuracy and precisionwere≤3%
and ≤1%, and the inter-run accuracy and precision were ≤4% and
≤3%, respectively.
TMZ interference study
For the CASE 1Y05 clinical trial [6], the maximum dose of TMZ
was scheduled to be 150mg/m2/day. According to the published
reports [14–17], maximum concentrations (Cmax) of TMZ in human
plasma fromclinical trialswerebelow10g/ml by suchdosing reg-
imen. Hence, the TMZ interference study was conducted using MX
QCs (low, mid, high) containing TMZ concentration of 20.0g/ml
(>2 times ofCmax). Itwas not only themass chromatograms showed
no interferences from TMZ at the mass transitions of MX and the
IS (data not shown), but also there were no significant differences
observed between the results of MX QCs with and without TMZ
(Table 7). Therefore, the presence of TMZ in human plasma does
not affect the accurate determination of MX in plasma samples.
Table 8
Stability study of MX under various test conditions.
Condition T (◦C) Samplea Period Recovery± SD
(%) (n=6)
Refrigerator 4 Stock solution 5 months 96.4 ± 7
Bench-top 23 Stock solution 18h 98.4 ± 6
Bench-top 23 Low QC 18h 89.4 ± 4
Mid QC 18h 94.5 ± 4
High QC 18h 95.7 ± 2
Autosampler 15 Low QC 3 days 90.7 ± 6
Mid QC 3 days 94.5 ± 5
High QC 3 days 96.9 ± 3
Freeze & thaw −70–23 Low QC 3 cycles 96.6 ± 2
Mid QC 3 cycles 94.4 ± 2
High QC 3 cycles 96.2 ± 2
Deep freezer
(long-term)
−70 Low QC 5 months 95.7 ± 3
Mid QC 5 months 101 ± 2
High QC 5 months 103 ± 2
a The concentration of MX stock solution was 2.00mg/ml which was measured
by serial dilution to 45.0ng/ml in 1% formic acid. The concentration of MX in LQC,
MQC and HQC were 3.50, 45.0 and 450ng/ml, respectively.
Stability
The stability of MX in human whole blood until separated into
plasma and storage was evaluated in this work. At 70min after
infusion, 5 tubes of blood (2ml each) from a patient underwent
MX therapy were drawn (<2min) using lithium heparinized tubes
(green top) and kept in an ice bath before centrifugation. Following
the detail procedure specified in Section 2.7, the blood samples
were centrifuged at 0, 30, 60, 90, and 120min after drawing, and
the plasma samples were analyzed by the LC–MS/MS method at
a later time. The measured MX concentrations from the patient
were 10.5, 10.6, 10.4, 10.3 and 10.5ng/ml, respectively, which
gave a mean value of 10.5ng/ml, a standard deviation of 0.1ng/ml,
and a %CV of 1%. This study revealed that there was no significant
changes in MX concentration in human whole blood over a period
of 2hours when samples were kept in an ice bath. MX is stable in
whole blood by following the sampling procedure specified in the
CASE 1Y05 protocol [6].
The stability of a test sample (i.e., stock solution or plasma
QC) was determined by the mean-peak-area ratio of the deriva-
tized MX to the derivatized IS from six parallel measurements
of six test solutions over that of the freshly prepared test solu-
tions, which was expressed as percent recovery. As shown in
Table 9
Example of incurred patient sample re-analysis.
Measured [MX] (ng/ml)
Patient sampling schedule (h) First analysis Re-analysis after 9 months E (ng/ml)a %REb
Pre-dose No peak No peak Not applicable Not applicable
0.250 5.36 5.69 0.33 6.2
0.500 8.95 10.2 1.25 14.0
0.750 16.2 18.2 2.0 12.3
0.983 20.5 22.1 1.6 7.8
1.17 25 27.1 2.1 8.4
2.00 24.2 24.3 0.1 0.4
4.00 18.3 20 1.7 9.3
6.00 19 19.5 0.5 2.6
8.00 18.9 17.5 −1.4 −7.4
12.0 15.6 16.2 0.6 3.8
24.0 13.3 13.2 −0.1 −0.8
48.0 9.46 10 0.54 5.7
72.0 6.56 6.46 −0.10 −1.5
96.0 4.46 4.76 0.3 6.7
120 3.55 3.69 0.14 3.9
168 2.11 2.29 0.18 8.5
192 1.55 1.76 0.21 13.5
216 1.22 1.39 0.17 13.9
a E (error) = value of first analysis−value of re-analysis.
b %RE (percent relative error) = (error/value of first analysis)×100%.
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Fig. 4. Representative plasma concentration-time profiles of MX in patients. (A)
Dosing regimen: MX (iv continuous infusion), 15mg/m2/day for 5 days; TMZ (oral
once daily), 100mg/m2/day for 5 days. (B) Dosing regimen: MX (single 1-h iv infu-
sion), 15mg/m2/day; and TMZ (oral once daily), 100mg/m2/day for 5 days.
Table 8, the recoveries of stock solutions were 96.4–98.4% for
refrigerator (4 ◦C) and bench top (23 ◦C); and the recoveries of
QC samples at three concentrations (3.50, 45.0 and 450ng/ml)
were 89.4–95.7%, 90.7–96.9%, 94.4–96.6%, and 95.7–103% for
bench top, autosampler (15 ◦C), three freeze-and-thaw cycles
(−70–23 ◦C), and long-term storage (5 months), respectively.
The data indicated that MX was stable under all tested
conditions.
Application of the method to the first-in-human MX clinical
trial
The LC–MS/MS method has been applied to the PK study of
MX in patients with advanced solid tumors by two dosing regi-
mens (120-h iv continuous infusion and1-h iv infusion). The typical
concentration-time profiles of MX in patients by 120-h and 1-h iv
infusion of MX were shown in Fig. 4. The PK parameters of first six
patients (16 cycles) by 120-h iv continuous infusion had a mean
elimination half-life (t1/2) of 45.07h, and a mean maximum con-
centration (Cmax) of 40.62ng/ml. The initial data demonstrated that
MX has a distinct PK profile in humans compared to that in mice
[10], which permitted an amendment to the initial regimen to a
more convenient 1-h infusion regimen. The PK parameters of MX
in 20 patients (46 cycles) with 1-h iv infusion had a mean t1/2 of
54.21h, and a mean Cmax of 14.98ng/ml. The t-test at 95% con-
fidence level revealed that there was no significant difference in
half-life estimates between the 120-h and 1-h infusion regimens.
Incurred sample re-analysis
As part of the method validation, plasma samples from two
patients’ treatment cycles were re-analyzed from their initial anal-
yses after 9-month storage at −70 ◦C. The results indicated that the
percent relative errors (%RE) between the two separate analyses
over a period of 9 months were all less than 15%. Table 9 showed
an example of such re-analysis. This study further demonstrated
the stability of long-term sample storage and the robustness of the
LC–MS/MS method.
Conclusion
An LC–MS/MS method for the quantitative determination of
MX in human plasma has been developed and validated. In this
work, MX and MX-d3 (IS) was derivatized directly in plasma with
4-(N,N-diethylamino)benzoaldehyde under acidic conditions. The
derivatized MX could be extracted from human plasma by methyl
tert-butyl ether and be readily separated from the derivatizing
agent by Waters Xterra C18 column. Detection of the derivatized
MX and IS was carried out by positive turbo-ion-spray MS/MS in
MRM mode. Quantitation of MX was accomplished by internal
calibration. Thismethod has been successfully applied to the deter-
mination of MX in plasma samples from the first-in-human MX
clinical trial.
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